Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade D 7.58 -0.66% -0.05
CCXI closed down 0.66 percent on Tuesday, September 17, 2019, on 72 percent of normal volume. It was able to find support at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CCXI trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -0.66%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.66%
Upper Bollinger Band Walk Strength -0.66%
Inside Day Range Contraction -0.66%
50 DMA Support Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%

Older signals for CCXI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Monoclonal Antibodies Autoimmune Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Immunosuppressants Atopic Dermatitis Diabetic Nephropathy Glioblastoma Multiforme Kidney Disease Biotie Therapies Dermatitis Inflammatory Disorders Janus Kinase Inhibitor Inflammatory Disease
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.98
52 Week Low 6.16
Average Volume 349,294
200-Day Moving Average 10.2919
50-Day Moving Average 7.462
20-Day Moving Average 7.0725
10-Day Moving Average 7.342
Average True Range 0.4202
ADX 33.36
+DI 26.6772
-DI 11.9056
Chandelier Exit (Long, 3 ATRs ) 7.1694
Chandelier Exit (Short, 3 ATRs ) 7.7606
Upper Bollinger Band 7.8558
Lower Bollinger Band 6.2892
Percent B (%b) 0.82
BandWidth 22.150583
MACD Line 0.0691
MACD Signal Line -0.0665
MACD Histogram 0.1356
Fundamentals Value
Market Cap 369.19 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -12.23
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.09
Resistance 3 (R3) 8.10 7.95 8.01
Resistance 2 (R2) 7.95 7.82 7.94 7.98
Resistance 1 (R1) 7.76 7.74 7.69 7.75 7.95
Pivot Point 7.61 7.61 7.57 7.60 7.61
Support 1 (S1) 7.42 7.48 7.35 7.41 7.21
Support 2 (S2) 7.27 7.40 7.26 7.18
Support 3 (S3) 7.08 7.27 7.16
Support 4 (S4) 7.07